PwC’s midyear outlook has now put the official stamp on what we have tracked since January: 2026 is a historic dealmaking year. The firm reported that biopharma deal value surpassed $65 billion in Q1 alone—nearly double the level seen a year earlier—with 16 transactions exceeding $1 billion. PwC declared the biopharma ecosystem “back to full health” and said activity was “focused on differentiated science, GLP-1 expansion and next-generation modalities including RNA medicines, antibody-drug conjugates and gene editing.” BioSpace added that “precision science is ruling the M&A scene as pharmas prepare for loss of exclusivity on key products.” The PwC data align with every other tracker we have referenced this year: CNBC’s $106 billion through early June, Reuters’ $84 billion Q1, BioWorld’s $93 billion through April. The directional signal is the same across every dataset. Meanwhile, Eli Lilly acquired 4E Therapeutics for oral non-opioid pain—its 13th deal of 2026—adding yet another therapeutic area to a portfolio that now spans nine. UniQure received an FDA reversal allowing it to file for accelerated approval of its Huntington’s disease gene therapy. Jazz signed a $56 million upfront TCE discovery deal with AbCellera. And the FDA approved the first oral carbapenem antibiotic for complicated urinary tract infections.
PwC: Biopharma Ecosystem Is “Back to Full Health”
What Happened: PwC’s Pharmaceutical and Life Sciences US Deals 2026 midyear outlook reported that biopharma dealmaking strengthened sharply, with deal value surpassing $65 billion in Q1—nearly double the prior year and one of the strongest quarterly performances in recent history.
What PwC Found
The PwC analysis identified several key dynamics driving the M&A surge:
16 transactions exceeded $1 billion in Q1 alone. The concentration of large deals reflects a market where companies are acquiring late-stage, de-risked assets at premium valuations rather than making small speculative bets. The average deal size has risen accordingly—CNBC/PitchBook reported the average at $527 million, up 44% from $365 million in 2025.
Activity focused on differentiated science, GLP-1 expansion, and next-generation modalities. PwC specifically called out RNA medicines, ADCs, and gene editing as the modality categories driving deal flow. This maps directly to the deals we have covered: Lilly’s Ascidian (RNA exon editing), Merck’s sac-TMT (ADC), Lilly’s Profluent (gene editing), and dozens of others across these categories.
Large drugmakers moved to replenish pipelines ahead of looming patent expiries. The patent cliff—hundreds of billions of dollars in branded drug revenue facing loss of exclusivity by 2030—is the structural driver behind the M&A surge. Companies are not buying because valuations are attractive (though they are). They are buying because they must replace the revenue they are about to lose.
The IPO window is open. PwC noted that biotechs should be prepared with a dual-track process (IPO and M&A) to maximize optionality. The 2026 IPO market has produced $3.6 billion-plus in proceeds across 13 offerings, with a median raise of approximately $300 million. Companies that prepare for both an IPO and a potential acquisition simultaneously can negotiate from a stronger position—an acquirer offering a premium below what public markets would value the company at has less leverage against a company with an active IPO filing.
The dual-track advice is particularly relevant in the current environment because the M&A and IPO markets are both running hot simultaneously—a combination that has not occurred since 2021. When both exit paths are open, biotech companies have maximum leverage. When only one is open (M&A without IPO, as in 2022 and 2023), acquirers have the upper hand. PwC’s observation that both markets are functioning well reinforces the “back to full health” assessment and suggests that the current favorable conditions could persist through at least the second half of 2026.
PwC in Context
The PwC $65 billion Q1 figure uses a methodology focused on U.S. pharma and life sciences deals above $100 million. Other trackers capture broader scope: Reuters/Dealogic reported $84 billion in Q1 (global biopharma M&A), BioWorld tracked $93 billion through April (global biopharma deals), and CNBC/PitchBook reported $106 billion through early June (global biotech M&A). The methodological differences explain the numerical variation, but the directional signal is unanimous: 2026 is running at approximately double the pace of 2025, and the second half has catalysts (Revolution approval, Medicare Bridge launch, BIO International partnering, Section 232 tariff deadlines) that could sustain or accelerate the pace.
Lilly Acquires 4E Therapeutics for Non-Opioid Pain — Deal Number 13
What Happened: Lilly acquired 4E Therapeutics, adding a pipeline of oral MNK (MAP kinase-interacting kinase) inhibitors designed to treat chronic pain without CNS side effects. Financial terms were not disclosed. This is Lilly’s 13th announced deal of 2026.
Why Non-Opioid Pain Matters
The chronic pain market is one of the largest unmet needs in medicine, but it has been constrained by the limitations and risks of existing therapies. Opioids are effective but carry addiction risk that has produced a national crisis. NSAIDs (ibuprofen, naproxen) work for mild-to-moderate pain but cause gastrointestinal and cardiovascular complications with long-term use. Gabapentinoids (pregabalin, gabapentin) help with nerve pain but cause sedation, dizziness, and cognitive impairment. None of these options are ideal for chronic pain management.
MNK inhibitors represent a novel mechanism that targets pain signaling pathways without engaging the CNS reward pathways responsible for opioid addiction or the sedation pathways that limit gabapentinoids. An oral non-opioid pain medication that effectively manages chronic pain without addiction risk, sedation, or significant gastrointestinal toxicity would address a gap that has persisted for decades despite enormous clinical demand.
Lilly at 13 Deals
The 4E acquisition adds chronic pain to a therapeutic footprint that now spans nine areas: obesity/metabolic, oncology, cell therapy, narcolepsy, gene editing/delivery, myelofibrosis, vaccines/infectious disease, kidney disease (RNA exon editing), and now pain. Total disclosed deal value exceeds $30 billion across 13 transactions in under six months.
The pain space connects to Lilly’s broader platform in ways that are not immediately obvious. Many chronic pain patients are also obese—obesity increases the burden on joints, the spine, and soft tissues, making musculoskeletal pain one of the most common comorbidities. A company that can treat obesity (Foundayo, Zepbound, retatrutide), manage the chronic pain associated with obesity (4E MNK inhibitors), and address the cardiometabolic consequences of both (Foundayo T2D) has a comprehensive cardiometabolic-pain franchise that no competitor can match. Whether this cross-therapeutic synergy is intentional or coincidental will become clearer at the December 7 Investment Community Meeting.
UniQure Plans Q3 Huntington’s Gene Therapy Filing After FDA Reversal
What Happened: UniQure announced plans for a Q3 2026 submission of its Huntington’s disease gene therapy after the FDA reversed its previous position and agreed to accept an accelerated approval filing. Fierce Biotech reported the FDA “gave the biotech the OK to file for accelerated approval after previously demanding data from another trial.”
Why the FDA Reversal Matters
Huntington’s disease is a fatal neurodegenerative disorder caused by a single genetic mutation (an expanded CAG repeat in the huntingtin gene). The disease causes progressive motor dysfunction, cognitive decline, and psychiatric symptoms, typically beginning in the 30s or 40s and leading to death within 15 to 20 years of symptom onset. There are no approved disease-modifying treatments. Current therapies manage symptoms but do not slow the underlying neurodegeneration.
The FDA’s initial demand for additional trial data before accepting a filing was a significant setback for UniQure. Gene therapy development for neurodegenerative diseases is exceptionally difficult—the trials are long, the endpoints are complex, and the patient population is small. Requiring data from an additional trial would have added years to the development timeline for a disease where patients have no other options.
The reversal—the FDA agreeing to accept an accelerated approval filing based on available data—is one of the most significant regulatory decisions for the rare disease community this year. Accelerated approval allows the FDA to approve a drug based on a surrogate endpoint (a biomarker that is reasonably likely to predict clinical benefit) with a requirement for post-marketing confirmatory studies. For Huntington’s, the surrogate endpoint would likely involve measurement of mutant huntingtin protein levels in cerebrospinal fluid or brain imaging metrics that correlate with disease progression.
If accepted and approved, this would be one of the most consequential gene therapy approvals in history—the first disease-modifying treatment for a fatal neurodegenerative disease with a clearly identified genetic cause.
Jazz Signs TCE Discovery Deal with AbCellera
What Happened: Jazz Pharmaceuticals signed a preclinical research collaboration with AbCellera for next-generation T-cell engager (TCE) discovery. Jazz pays $56 million upfront and is eligible to pay up to $792 million in milestones for each of three initial programs, plus tiered royalties.
Why This Matters: T-cell engagers are bispecific antibodies designed to simultaneously bind a tumor antigen and a T-cell surface protein (typically CD3), physically bringing immune cells into contact with cancer cells to trigger killing. The modality has shown significant clinical promise in hematologic malignancies—J&J’s teclistamab and Pfizer’s elranatamab are approved for multiple myeloma—and is now being explored in solid tumors where the challenge of getting T-cells to infiltrate tumors is greater.
Jazz’s existing oncology portfolio is anchored in hematology, and the AbCellera collaboration diversifies the company into bispecific antibody capabilities through AbCellera’s high-throughput antibody discovery platform. The $792 million per-program milestone structure (across three programs) reflects the potential for significant value if the TCE candidates advance through development. AbCellera’s platform has become one of the industry’s most prolific antibody discovery engines, with partnerships spanning multiple therapeutic areas and modalities.
FDA Approves First Oral Carbapenem for Complicated UTIs
What Happened: The FDA approved GSK and Spero Therapeutics’ Utebzi (tebipenem pivoxil) as the first oral carbapenem antibiotic for complicated urinary tract infections.
Why This Matters: Carbapenems are among the most powerful antibiotics available and have traditionally been reserved as last-resort treatments administered intravenously in hospital settings. An oral formulation fundamentally changes how these infections can be managed. Patients with complicated UTIs caused by resistant bacteria—who would otherwise require hospitalization for IV antibiotic therapy—can now potentially be treated in outpatient settings. This reduces hospital stays, lowers healthcare costs, and improves patient convenience.
The approval also addresses a critical gap in the antimicrobial resistance (AMR) treatment landscape. Urinary tract infections are among the most common bacterial infections, and resistance rates to standard oral antibiotics (fluoroquinolones, trimethoprim-sulfamethoxazole) have risen steadily. Having an oral carbapenem available gives physicians a powerful outpatient option for infections that resist first-line treatments.
The timing is relevant to multiple threads we have been tracking. Lilly acquired LimmaTech Biologics for up to $780 million in May to develop vaccines against AMR pathogens including Staphylococcus aureus and Neisseria gonorrhoeae. The Utebzi approval and the LimmaTech acquisition represent two different approaches to the same problem: treating resistant infections (Utebzi) and preventing them (LimmaTech vaccines). Both are needed as the AMR crisis continues to intensify globally—the WHO estimates that drug-resistant infections contribute to nearly 5 million deaths annually worldwide. The India cisplatin/carboplatin shortage we reported yesterday underscores how fragile the generic antibiotic and chemotherapy supply chains remain. Having a new oral antibiotic option that can keep patients out of hospitals reduces the strain on healthcare systems that are simultaneously managing oncology drug shortages, staffing challenges, and the residual effects of pandemic-era disruptions.
Strategic Themes
1. PwC’s “Back to Full Health” Declaration Makes the 2026 M&A Thesis Consensus
When PwC declares the biopharma ecosystem “back to full health” and reports Q1 deal value at $65 billion (nearly double the prior year), the thesis we have tracked since January is no longer an observation—it is consensus. Every major advisory firm, data provider, and industry analyst now agrees that 2026 is a historic dealmaking year driven by patent cliff urgency, abundant cash, de-risked acquisition targets, and a productive pipeline of external innovation from China, European mid-caps, and U.S. clinical-stage biotechs.
2. Lilly’s 13th Deal Raises the Question of Whether There Is a Ceiling
Thirteen deals. Nine therapeutic areas. Eight modalities. More than $30 billion in disclosed value. At what point does the pace of acquisition exceed the organizational capacity to integrate and advance the acquired assets? PwC noted that companies should pursue differentiated science—Lilly is doing that across a broader front than any competitor. But differentiation across nine therapeutic areas simultaneously requires management bandwidth that no pharmaceutical company has been tested on at this scale. BIO International next week may provide the first post-ADA, post-PwC management commentary on how Lilly plans to prioritize.
3. The UniQure FDA Reversal Is the Most Important Regulatory Decision for Rare Disease This Month
The FDA agreeing to accept a Huntington’s gene therapy filing after previously demanding additional trial data is a significant shift. It reflects a pragmatic assessment that for a fatal disease with no disease-modifying treatments, the available data may be sufficient for accelerated approval with post-marketing commitments. This decision could influence how the FDA evaluates other gene therapy programs targeting rare neurodegenerative diseases with small patient populations and limited clinical data.
4. The First Oral Carbapenem Fills a Gap That Has Existed for Decades in AMR Treatment
Carbapenems have been IV-only for their entire history. An oral formulation for complicated UTIs is a genuine first. For the AMR treatment landscape, Utebzi represents the kind of incremental but meaningful innovation that the antibiotics field needs: not a new mechanism of action, but a new route of administration that makes an existing class of antibiotics accessible to outpatient settings where most infections are actually managed.
Frequently Asked Questions
What did PwC report?
Q1 2026 biopharma deal value surpassed $65 billion, nearly double the prior year. Sixteen transactions exceeded $1 billion. PwC declared the ecosystem “back to full health” and noted activity was focused on differentiated science, GLP-1 expansion, and next-generation modalities.
What is Lilly’s 13th deal?
4E Therapeutics, a company developing oral MNK inhibitors for chronic pain without CNS side effects. Financial terms were not disclosed. Lilly’s portfolio now spans nine therapeutic areas across 13 deals totaling more than $30 billion in disclosed value.
What happened with UniQure?
The FDA reversed its previous position and agreed to accept an accelerated approval filing for UniQure’s Huntington’s disease gene therapy. The company plans a Q3 2026 submission. Huntington’s has no approved disease-modifying treatments.
What is the Jazz/AbCellera deal?
A TCE (T-cell engager) discovery collaboration. $56 million upfront, up to $792 million in milestones per program across three initial programs. AbCellera provides antibody discovery. Jazz gains bispecific oncology capabilities.
What is Utebzi?
The first oral carbapenem antibiotic, approved for complicated urinary tract infections. GSK and Spero Therapeutics. Carbapenems were previously IV-only. The oral formulation enables outpatient treatment of resistant UTIs.
When is BIO International?
Opens Monday, June 22 through June 25 in San Diego. Four days out.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
PwC Midyear. We analyze what $65B in Q1 (nearly 2x YoY) tells us about H2 dealmaking expectations, compare PwC’s methodology to other M&A trackers, and assess whether the pace is sustainable through the Section 232 tariff deadline and the Revolution approval cycle.
Huntington’s Gene Therapy. We assess why the FDA reversal matters for the rare disease gene therapy pipeline, what accelerated approval based on surrogate endpoints means for Huntington’s, and how the decision could influence regulatory approaches to other neurodegenerative conditions.
Lilly Deal 13. We analyze how non-opioid pain fits a portfolio spanning nine therapeutic areas, assess the MNK mechanism’s differentiation from existing pain therapies, and evaluate the cross-therapeutic synergy between pain, obesity, and cardiometabolic disease.
Plus: Jazz/AbCellera TCE analysis, Utebzi AMR treatment landscape, BIO International preview, Revolution filing watch, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
